Press coverage about Trevena (NASDAQ:TRVN) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Trevena earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.5518380985402 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of equities analysts have commented on TRVN shares. ValuEngine lowered shares of Trevena from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Zacks Investment Research lowered shares of Trevena from a “hold” rating to a “sell” rating in a report on Wednesday, July 26th. Oppenheimer Holdings, Inc. set a $8.00 price objective on shares of Trevena and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, Cowen and Company reiterated a “buy” rating and issued a $10.00 price objective on shares of Trevena in a report on Friday, August 4th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have given a buy rating to the company. Trevena presently has an average rating of “Buy” and an average target price of $10.56.
Shares of Trevena (NASDAQ:TRVN) opened at 2.78 on Wednesday. The stock has a 50 day moving average of $2.46 and a 200 day moving average of $2.94. Trevena has a 52-week low of $2.15 and a 52-week high of $8.00. The company’s market cap is $165.95 million.
Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.35). On average, equities analysts anticipate that Trevena will post ($1.41) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Trevena (TRVN) Share Price” was published by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2017/09/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-trevena-trvn-share-price.html.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with MarketBeat.com's FREE daily email newsletter.